Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30816273)

  • 1. Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
    Costamagna A; Rossi Sebastiano M; Natalini D; Simoni M; Valabrega G; Defilippi P; Visentin S; Ermondi G; Turco E; Caron G; Cabodi S
    Sci Rep; 2019 Feb; 9(1):3089. PubMed ID: 30816273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.
    Tornillo G; Bisaro B; Camacho-Leal Mdel P; Galiè M; Provero P; Di Stefano P; Turco E; Defilippi P; Cabodi S
    Eur J Cell Biol; 2011; 90(2-3):237-48. PubMed ID: 20961652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p130Cas is an essential transducer element in ErbB2 transformation.
    Cabodi S; Tinnirello A; Bisaro B; Tornillo G; del Pilar Camacho-Leal M; Forni G; Cojoca R; Iezzi M; Amici A; Montani M; Eva A; Di Stefano P; Muthuswamy SK; Tarone G; Turco E; Defilippi P
    FASEB J; 2010 Oct; 24(10):3796-808. PubMed ID: 20505116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion.
    Sciortino M; Camacho-Leal MDP; Orso F; Grassi E; Costamagna A; Provero P; Tam W; Turco E; Defilippi P; Taverna D; Cabodi S
    Sci Rep; 2017 Apr; 7(1):1145. PubMed ID: 28442738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells.
    Pincini A; Tornillo G; Orso F; Sciortino M; Bisaro B; Leal Mdel P; Lembo A; Brizzi MF; Turco E; De Pittà C; Provero P; Medico E; Defilippi P; Taverna D; Cabodi S
    Cell Cycle; 2013 Aug; 12(15):2409-22. PubMed ID: 23839042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
    Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R
    Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.
    Bisaro B; Montani M; Konstantinidou G; Marchini C; Pietrella L; Iezzi M; Galiè M; Orso F; Camporeale A; Colombo SM; Di Stefano P; Tornillo G; Camacho-Leal MP; Turco E; Taverna D; Cabodi S; Amici A; Defilippi P
    Breast Cancer Res; 2012 Oct; 14(5):R137. PubMed ID: 23098208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
    Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
    D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
    J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ErbB2 signaling network as a target for breast cancer therapy.
    Badache A; Gonçalves A
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):13-25. PubMed ID: 16947083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
    Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
    Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.